Paul Garofolo's guest appearances

Paul Garofolo

humanOS Radio

Biotech 2050 Podcast

Business Of Biotech

Brian Culley

Paul Wotton

Seth Lederman

Raman Sehgal

Caroline Loew

James Clear

Ben Miller

Chris Kresser

Andrew Hill

Jeff Chilton

Stephan Guyenet

Robert Gould

Richard Lin

Gary Taubes

Judith Campisi

OwlTail

Paul is the CEO &amp; Co-founder of Locus Biosciences. With a career that spans manufacturing, research &amp; development, information technology and corporate transformations, Paul brings a broad range of experience and capability to deliver on the Locus vision. Prior to Locus, Paul was Chief Technology Officer at Patheon Pharmaceuticals and also held the role of Global Head of Operations for Patheon’s Pharmaceuticals Development Services business unit. Paul previously served as Global Head of Manufacturing and Chief Information Officer at Valeant Pharmaceuticals, amount other roles. Paul was a Visiting Professor at North Carolina State University’s Poole College of Management and volunteered as an executive-in-residence for the HiTEC Graduate Program, NCSU’s Entrepreneurship Collaborative, where he identified the technology that would form the basis for Locus. Paul earned a BSBA in Management Information Systems from the University of Arizona and completed the Advanced Management Program at Harvard Business School.

107. Fighting infectious diseases with biologics, Paul Garofolo, Co-founder & CEO, Locus Biosciences

Locus Biosciences CEO Paul Garofolo built his biotech leadership career on the back of an MIS degree, having learned the business from the inside out via the tentacles of the IT networks at companies including Genentech, The Broadlane Group, Valeant Pharmaceuticals and Patheon. On today's episode of the Business of Biotech, Garofolo shares how a technologist's approach has helped shape the effort to develop precision therapeutics for infectious diseases at Locus, the company's decision to build its own cGMP manufacturing facility in Research Triangle, and the massive business opportunity the field addresses in the effort to overcome antibiotic resistance. Subscribe to the NEW #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!

Locus Biosciences CEO Paul Garofolo built his biotech leadership career on the back of an MIS degree, having learned the business from the inside out via the tentacles of the IT networks at companies including Genentech, The Broadlane Group, Valeant Pharmaceuticals and Patheon. On today's episode of the Business of Biotech, Garofolo shares how a technologist's approach has helped shape the effort to develop precision therapeutics for infectious diseases at Locus, the company's decision to build its own cGMP manufacturing facility in Research Triangle, and the massive business opportunity the field addresses in the effort to overcome antibiotic resistance. Subscribe to the NEW #BusinessofBiotech newsletter at <a href="https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/" rel="nofollow" target="_blank">bioprocessonline.com/bob</a> for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at <a href="https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/" rel="nofollow" target="_blank">bioprocessonline.com/bob</a>!

Precision Approach To Infectious Disease With Locus Biosciences' Paul Garofolo

If you are alive today, you've benefited greatly from humankind's ability to deftly handle infectious agents via antibiotic medications. In fact, probably the single greatest achievement of modern medicine remains our ability to thwart (many) deadly microorganisms.  But our high usage of antibiotics has put great pressure on these pathogenic bacteria to mutate for their own survival. As a result, deadly strains of bacteria have become more virulent and more resistant to our medications, creating so-called “superbugs.” For instance, an increasing percentage of tuberculosis cases worldwide are attributed to bacterial forms that are resistant to multiple drugs and require more complex treatments with an array of different medications. Eventually, former wonder drugs, like penicillin for instance, can be rendered ineffective.This is a very scary proposition and this problem is not likely to go away on its own. We need new ways to control bacterial infections and we need them fast. And that brings us to my guest today.In this episode of humanOS Radio, Dan speaks with Paul Garofolo. Paul is the CEO of Locus Biosciences, a biotech company that is developing a novel class of antimicrobials that take advantage of the CRISPR-Cas system. If this pans out, it would offer a viable alternative to conventional antibiotics, and would presumably be less subject to the known mechanisms of drug resistance. Secondly, this method could be targeted to specific pathogenic bacteria, thus leaving your friendly bugs alone. This seems like a win-win that is both lifesaving and health promoting, potentially (depending on the context).

If you are alive today, you've benefited greatly from humankind's ability to deftly handle infectious agents via antibiotic medications. In fact, probably the single greatest achievement of modern medicine remains our ability to thwart (many) deadly microorganisms.  But our high usage of antibiotics has put great pressure on these pathogenic bacteria to mutate for their own survival. As a result, deadly strains of bacteria have become more virulent and more resistant to our medications, creating so-called “superbugs.” For instance, an increasing percentage of tuberculosis cases worldwide are attributed to bacterial forms that are resistant to multiple drugs and require more complex treatments with an array of different medications. Eventually, former wonder drugs, like penicillin for instance, can be rendered ineffective. This is a very scary proposition and this problem is not likely to go away on its own. We need new ways to control bacterial infections and we need them fast. And that brings us to my guest today. In this episode of humanOS Radio, Dan speaks with Paul Garofolo. Paul is the CEO of Locus Biosciences, a biotech company that is developing a novel class of antimicrobials that take advantage of the CRISPR-Cas system. If this pans out, it would offer a viable alternative to conventional antibiotics, and would presumably be less subject to the known mechanisms of drug resistance. Secondly, this method could be targeted to specific pathogenic bacteria, thus leaving your friendly bugs alone. This seems like a win-win that is both lifesaving and health promoting, potentially (depending on the context).

#033 - Antibiotics Are Losing Efficacy, CRISPR May Save Us - Paul Garofolo, CEO Locus Bio